Hikma Pharmaceuticals (LON:HIK) Receives “Buy” Rating from Deutsche Bank Aktiengesellschaft

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reissued by equities researchers at Deutsche Bank Aktiengesellschaft in a note issued to investors on Friday,Digital Look reports. They presently have a GBX 1,950 price target on the stock. Deutsche Bank Aktiengesellschaft’s price objective would indicate a potential upside of 13.90% from the stock’s current price.

A number of other equities analysts have also recently issued reports on the company. Jefferies Financial Group increased their target price on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Citigroup restated a “buy” rating on shares of Hikma Pharmaceuticals in a report on Thursday, July 16th. Finally, Berenberg Bank reaffirmed a “buy” rating and set a GBX 1,800 price objective on shares of Hikma Pharmaceuticals in a research report on Tuesday, April 28th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Hikma Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of GBX 2,038.

Hikma Pharmaceuticals Trading Up 0.8%

Shares of LON:HIK opened at GBX 1,712 on Friday. The firm has a market cap of £3.58 billion, a price-to-earnings ratio of 9.46, a PEG ratio of 2.38 and a beta of 0.65. Hikma Pharmaceuticals has a 12 month low of GBX 1,187 and a 12 month high of GBX 1,865. The company’s fifty day simple moving average is GBX 1,529.89 and its 200 day simple moving average is GBX 1,451.75. The company has a quick ratio of 1.27, a current ratio of 1.82 and a debt-to-equity ratio of 61.84.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.